Literature DB >> 17496731

Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders.

Masami Sasaki1, Takahisa Kawano, Takako Saito, Miho Yuzawa, Tomoyuki Saito, Aki Ikoma, Hiroyuki Tamemoto, Masanobu Kawakami, San-e Ishikawa.   

Abstract

The present study was undertaken to determine serum adiponectin level in patients with cerebral infarction and to further analyze any difference in serum adiponectin levels among atherosclerotic disorders. One hundred fifty-two subjects with atherosclerotic disorders were enrolled, 110 males and 42 females, with the age of 67.0 +/- 9.9 years (mean +/- SD). They were divided into 62 patients with cerebral infarction, 48 patients with ischemic heart disease, and 42 patients with arteriosclerosis obliterans. Thirty-two subjects matched by age, gender, and body mass index served as controls. Serum adiponectin levels were 7.2 +/- 0.6 microg/mL (mean +/- SE) in the patients with cerebral infarction, 7.2 +/- 0.8 microg/mL in those with ischemic heart disease, and 6.9 +/- 0.9 microg/mL in those with arteriosclerosis obliterans. They were significantly less than the level of 12.6 +/- 1.9 microg/mL in the control group (P < 0.01). However, there was no difference in serum adiponectin level among three groups of atherosclerotic disorders. In the patients with acute cerebral infarction, serum adiponectin level was temporarily reduced from 7.3 +/- 0.9 to 6.2 +/- 0.8 microg/mL 14 days after the hospitalization (P < 0.01), followed by recovery to the basal value. The present findings indicate that serum adiponectin levels are equivalently reduced in patients with atherosclerotic disorders, and that serum adiponectin is changeable under acute phase of cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496731     DOI: 10.1097/MAJ.0b013e318031b7af

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

Review 1.  Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Biochim Biophys Acta       Date:  2015-11-09

2.  The association between serum adiponectin and 3-month outcome after ischemic stroke.

Authors:  Zengliang Wang; Bo Li; Yongxin Wang; Aisha Maimaitili; Hu Qin; Geng Dangmurenjiafu; Shuo Wang
Journal:  Cardiovasc Diabetol       Date:  2019-08-14       Impact factor: 9.951

3.  Relationship between adiponectin multimer levels and subtypes of cerebral infarction.

Authors:  Noriko Tagawa; Aya Fujinami; Shigeatsu Natsume; Shigeto Mizuno; Ikuo Kato
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

4.  Therapeutic window of globular adiponectin against cerebral ischemia in diabetic mice: the role of dynamic alteration of adiponectin/adiponectin receptor expression.

Authors:  Wenying Song; Fan Guo; Haixing Zhong; Lixin Liu; Rui Yang; Qiang Wang; Lize Xiong
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

Review 5.  Diabetes Mellitus: A Path to Amnesia, Personality, and Behavior Change.

Authors:  Rahnuma Ahmad; Kona Chowdhury; Santosh Kumar; Mohammed Irfan; Govindool Sharaschandra Reddy; Farhana Akter; Dilshad Jahan; Mainul Haque
Journal:  Biology (Basel)       Date:  2022-02-28

6.  Adiponectin Treatment Attenuates Cerebral Ischemia-Reperfusion Injury through HIF-1α-Mediated Antioxidation in Mice.

Authors:  Chan Zhang; Luming Zhen; Zongping Fang; Liang Yu; Yuanyuan Zhang; Haidong Wei; Junfeng Jia; Shiquan Wang
Journal:  Oxid Med Cell Longev       Date:  2021-07-14       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.